Bora Pharmaceuticals, a fast-growing contract development and manufacturing organization (CDMO), is investing more than $10 million over the next 2 years to expand its oral solid dose capabilities across facilities in Zhunan, Taiwan and Mississauga, Ontario.
The company’s CEO, Bobby Sheng, said the expansion will position the company for sustained growth over the next few years to help meet new client demands.
Coinciding with the investment, Bora Mississauga has relaunched a pilot facility that was purpose-built for development and clinical manufacturing and is separate from its commercial manufacturing activities.
